Jaap JanBoelensMDPhD(He/Him)

Pediatric Hematology & Oncology • New York, NY

Chief, Transplantation and Cellular Therapies

Overview of Dr. Boelens

Dr. Jaap Jan Boelens is a pediatric-oncologist in New York, NY at Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He is Prof of Pediatrics at WCMC. He has experience in transplantation (and gene-therapy) for sickle cell disease, lysosomal storage diseases and refractory leukemias. Research: PKPD and immune reconstitution and has 300+ publications and 17K+ citations!

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(929) 254-4497

Education & Training

Utrecht University Faculty of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2019 - 2025

Clinical Trials

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies Start of enrollment: 2021 Dec 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Start of enrollment: 2020 Nov 20
Recruiting
Phase 2
Roles: Contact
Conditioning SCID Infants Diagnosed Early Start of enrollment: 2018 Oct 22
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT Start of enrollment: 2022 Mar 31
Recruiting
Phase 1, Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2023 Feb 09
Recruiting
Phase 2
Roles: Contact
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Start of enrollment: 2022 Oct 06
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition Start of enrollment: 2023 Mar 15
Recruiting
Phase 2
A Study of Emapalumab for Pediatric Aplastic Anemia Start of enrollment: 2024 May 21
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

201 citations
Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharm...
Rick Admiraal, Charlotte van Kesteren, Cornelia M. Jol-van der Zijde, Arjan C. Lankester, Marc Bierings
The Lancet. Haematology. 2015-05-01
59 citations
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
Mary Eapen, Tao Wang, Paul Veys, Jaap Jan Boelens, Andrew St. Martin
The Lancet. Haematology. 2017-07-01
158 citations
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J Curran, Steven P. Margossian, Nancy A. Kernan, Lewis B. Silverman, David A. Williams
Blood. 2019-12-26

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Jaap Jan Boelens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019